190 related articles for article (PubMed ID: 31099113)
21. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of beta-3 adrenergic agonists in treating neurogenic lower urinary tract dysfunction: A systematic review and meta-analysis.
Elkhashab MM; Alqahtani AM; Kim MH; Kim J; Kim JH; Jung JH
Investig Clin Urol; 2024 May; 65(3):217-229. PubMed ID: 38714512
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of PDE5-Is and α-1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs.
Sun X; Guan W; Liu H; Tang K; Yan L; Zhang Y; Zeng J; Chen Z; Xu H; Ye Z
BMC Urol; 2018 May; 18(1):30. PubMed ID: 29724204
[TBL] [Abstract][Full Text] [Related]
24. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
[TBL] [Abstract][Full Text] [Related]
25. New alpha blockers to treat male lower urinary tract symptoms.
Hwang EC; Gandhi S; Jung JH
Curr Opin Urol; 2018 May; 28(3):273-276. PubMed ID: 29613909
[TBL] [Abstract][Full Text] [Related]
26. Antimuscarinics and α-blockers or α-blockers monotherapy on lower urinary tract symptoms--a meta-analysis.
Hao N; Tian Y; Liu W; Wazir R; Wang J; Liu L; Wang K; Li H
Urology; 2014 Mar; 83(3):556-62. PubMed ID: 24361007
[TBL] [Abstract][Full Text] [Related]
27. Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series.
Engeler DS; Meyer D; Abt D; Müller S; Schmid HP
BMC Urol; 2015 Oct; 15():105. PubMed ID: 26498275
[TBL] [Abstract][Full Text] [Related]
28. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
Zhang J; Li X; Yang B; Wu C; Fan Y; Li H
World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
[TBL] [Abstract][Full Text] [Related]
30. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis.
Wang Y; Bao Y; Liu J; Duan L; Cui Y
Low Urin Tract Symptoms; 2018 Jan; 10(1):84-92. PubMed ID: 29341503
[TBL] [Abstract][Full Text] [Related]
31. Discontinuation of alpha-blocker therapy in men with lower urinary tract symptoms: a systematic review and meta-analysis.
van der Worp H; Jellema P; Hordijk I; Lisman-van Leeuwen Y; Korteschiel L; Steffens MG; Blanker MH
BMJ Open; 2019 Nov; 9(11):e030405. PubMed ID: 31699724
[TBL] [Abstract][Full Text] [Related]
32. The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review.
Tubaro A; Puccini F; De Nunzio C; Digesu GA; Elneil S; Gobbi C; Khullar V
Curr Urol Rep; 2012 Oct; 13(5):335-42. PubMed ID: 22886612
[TBL] [Abstract][Full Text] [Related]
33. Alpha blockers prior to removal of a catheter for acute urinary retention in adult men.
Zeif HJ; Subramonian K
Cochrane Database Syst Rev; 2009 Oct; (4):CD006744. PubMed ID: 19821385
[TBL] [Abstract][Full Text] [Related]
34. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.
Wang XH; Wang X; Shi MJ; Li S; Liu T; Zhang XH
Asian J Androl; 2015; 17(6):1022-32. PubMed ID: 25994648
[TBL] [Abstract][Full Text] [Related]
35. The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation.
Ginsberg DA; Boone TB; Cameron AP; Gousse A; Kaufman MR; Keays E; Kennelly MJ; Lemack GE; Rovner ES; Souter LH; Yang CC; Kraus SR
J Urol; 2021 Nov; 206(5):1097-1105. PubMed ID: 34495687
[TBL] [Abstract][Full Text] [Related]
36. Peripheral and Sacral Neuromodulation in the Treatment of Neurogenic Lower Urinary Tract Dysfunction.
Barboglio Romo PG; Gupta P
Urol Clin North Am; 2017 Aug; 44(3):453-461. PubMed ID: 28716325
[TBL] [Abstract][Full Text] [Related]
37. Neurogenic lower urinary tract dysfunction in the early disease phase of paediatric multiple sclerosis.
Scheepe JR; Wong YY; van Pelt ED; Ketelslegers IA; Catsman-Berrevoets CE; van den Hoek J; Hintzen RQ; Neuteboom RF
Mult Scler; 2016 Oct; 22(11):1490-1494. PubMed ID: 26589894
[TBL] [Abstract][Full Text] [Related]
38. Alpha-adrenoceptor antagonists in neurogenic lower urinary tract dysfunction.
Sullivan J; Abrams P
Urology; 1999 Mar; 53(3 Suppl 3a):21-7; discussion 27-8, 41-2. PubMed ID: 10094097
[TBL] [Abstract][Full Text] [Related]
39. Management of lower urinary tract dysfunction in multiple sclerosis: a systematic review and Turkish consensus report.
Çetinel B; Tarcan T; Demirkesen O; Özyurt C; Şen İ; Erdoğan S; Siva A
Neurourol Urodyn; 2013 Nov; 32(8):1047-57. PubMed ID: 23757108
[TBL] [Abstract][Full Text] [Related]
40. Alpha-blockers as medical expulsive therapy for ureteral stones.
Campschroer T; Zhu Y; Duijvesz D; Grobbee DE; Lock MT
Cochrane Database Syst Rev; 2014 Apr; (4):CD008509. PubMed ID: 24691989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
